Company news
Prokidney Corp. (NASDAQ:PROK) news
Prokidney Corp. news releases on 6ix. Latest, May 11, 2023: ProKidney Reports First Quarter Financial Results and Recent Corporate Highlights
Press releases — page 2
ProKidney Reports First Quarter Financial Results and Recent Corporate Highlights
May 10, 2023
ProKidney to Present at the BofA Securities Health Care Conference 2023
May 3, 2023
ProKidney Reports Fourth Quarter Financial Results and Recent Corporate Highlights
March 27, 2023
ProKidney to Participate in TD Cowen’s 43rd Annual Health Care Conference
March 2, 2023
ProKidney Announces Publication of Trial Design for Phase 2 Multicenter Clinical Trial of REACT for Late Stage 4 Diabetes-Related Chronic Kidney Disease
January 9, 2023
ProKidney to Present at the J.P. Morgan 41st Annual Healthcare Conference
December 21, 2022
ProKidney Reports Third Quarter 2022 Financial Results and Recent Corporate Highlights
November 13, 2022
ProKidney to Participate in Upcoming Investor Conferences
November 10, 2022
ProKidney Receives Allowance from the UK Medicines and Healthcare Products Regulatory Agency (MHRA) for proact 1 (REGEN-006) and EMA Scientific Advice on Phase 3 Protocols of REACT for Diabetic Chronic Kidney Disease
November 2, 2022
ProKidney Announces Multiple Abstracts Selected for Presentation at the American Society of Nephrology’s Kidney Week 2022
October 13, 2022
ProKidney to Present at the Jefferies Cell and Genetic Medicine Summit
September 22, 2022
ProKidney to Present at the Morgan Stanley 20th Annual Global Healthcare Conference
September 7, 2022
ProKidney Appoints Glenn Schulman, PharmD, MPH, as Senior Vice President of Investor Relations
August 30, 2022
ProKidney Strengthens Board of Directors with Appointments of Dr. John M. Maraganore and Jennifer Fox
August 10, 2022
ProKidney Corp. Reports Second Quarter 2022 Financial Results and Provides Business Update
August 10, 2022
ProKidney Appoints Kerry Cooper, M.D., as Senior Vice President of Medical Affairs
July 19, 2022
Social Capital Suvretta Holdings Corp. III Announces Reconvened Extraordinary General Meeting of Shareholders
July 7, 2022
Observed Safety Profile Supports Bilateral Dosing of ProKidney’s REACT™ – 007 Update
June 6, 2022
ProKidney to present at upcoming investor conferences
May 19, 2022
ProKidney and Social Capital Suvretta Holdings Corp. III (“SCS”) to Host Analyst and Investor Day on April 28, 2022
April 17, 2022
ProKidney confirms Phase 3 program for autologous kidney cell therapy REACT®
April 11, 2022
ProKidney Announces Online Publication of Trial Design for Phase II Multicenter Clinical Trial of REACT® Autologous Cell Therapy for Treatment of Chronic Kidney Disease
January 26, 2022
Revolutionary Chronic Kidney Disease Therapeutics Company ProKidney to Become Publicly Traded via Business Combination with Social Capital Suvretta Holdings Corp. III
January 17, 2022